泽璟制药(688266) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥143,420,460.04, representing a year-on-year increase of 130.67%[2] - The net profit attributable to shareholders was a loss of ¥31,366,912.30 for the quarter, with a cumulative loss of ¥97,902,983.29 year-to-date[2] - Total operating revenue for the first three quarters of 2024 reached ¥384,117,191.62, an increase of 36.3% compared to ¥282,104,804.49 in the same period of 2023[15] - Net profit for the third quarter was reported at -¥109,646,565.01, an improvement from -¥214,296,136.14 in the previous year[16] - The net profit for the first three quarters of 2024 was a loss of CNY 67,704,663.67, compared to a loss of CNY 184,664,524.78 in the same period of 2023[26] - The company reported a comprehensive loss of -¥83,611,486.06 for the quarter, an improvement from -¥212,200,009.58 in the previous year[17] Research and Development - Research and development expenses totaled ¥91,632,467.76 in Q3 2024, a decrease of 20.23% compared to the same period last year[2] - The ratio of R&D expenses to operating revenue was 63.89% for the quarter, down 120.86 percentage points year-on-year[4] - Research and development expenses for the first three quarters amounted to ¥272,787,045.80, down 18.6% from ¥335,190,822.91 in the same period last year[15] - Research and development expenses for the first three quarters of 2024 were CNY 241,537,837.74, a decrease from CNY 310,051,432.83 in the same period of 2023[24] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥2,967,147,910.00, reflecting a 2.77% increase from the end of the previous year[4] - The total liabilities increased to ¥1,664,341,911.75 from ¥1,242,369,776.94, representing a growth of 34%[15] - The total assets of the company as of September 30, 2024, amounted to ¥3,271,895,173.03, an increase from ¥2,901,876,252.46 at the end of 2023[22] - The company’s total liabilities increased to CNY 1,616,879,616.58 in the third quarter of 2024, compared to CNY 1,179,233,995.74 in the previous year[25] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 8,846[9] - ZELIN SHENG holds 49,910,527 shares, accounting for 18.85% of total shares[11] - The top ten shareholders include ZELIN SHENG and JACKIE ZEGI SHENG, who are identified as acting in concert[11] Cash Flow - The net cash flow from operating activities year-to-date was ¥66,647,070.57, primarily due to the receipt of exclusive sales promotion authorization fees of ¥28,000,000[8] - The net cash flow from operating activities for the first three quarters of 2024 was ¥66,647,070.57, a significant improvement compared to a net outflow of ¥229,219,463.44 in the same period of 2023[20] - Cash flow from operating activities generated a net inflow of CNY 76,531,835.04 in the first three quarters of 2024, a significant recovery from a net outflow of CNY 245,084,297.23 in the previous year[27] Inventory and Receivables - Accounts receivable increased to ¥132,638,815.48 from ¥101,139,998.16 year-over-year[12] - Inventory has risen to ¥160,289,459.88 compared to ¥110,852,343.86 in the previous year[13] - The company’s inventory increased to ¥160,289,459.88 from ¥110,852,343.86 year-over-year, representing a growth of approximately 45%[22] Financial Expenses - The company paid ¥40,182,246.97 in taxes during the third quarter of 2024, a significant increase from ¥15,040,583.30 in the same quarter of the previous year[20] - The company’s financial expenses included interest expenses of CNY 20,415,938.95 for the first three quarters of 2024, compared to CNY 16,014,630.61 in the same period of 2023[24]